Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2012 Nov;53(11):2143-50.
doi: 10.3109/10428194.2012.676173. Epub 2012 Aug 28.

Interim [(18)F]fluorodeoxyglucose positron emission tomography imaging in stage I-II non-bulky Hodgkin lymphoma: would using combined positron emission tomography and computed tomography criteria better predict response than each test alone?

Lale Kostakoglu  1 , Heiko Schöder, Jeffrey L Johnson, Nathan C Hall, Lawrence H Schwartz, David J Straus, Ann S LaCasce, Sin-Ho Jung, Nancy L Bartlett, George P Canellos, Bruce D Cheson; Cancer Leukemia Group B
Collaborators, Affiliations
Clinical Trial

Interim [(18)F]fluorodeoxyglucose positron emission tomography imaging in stage I-II non-bulky Hodgkin lymphoma: would using combined positron emission tomography and computed tomography criteria better predict response than each test alone?

Lale Kostakoglu et al. Leuk Lymphoma. 2012 Nov.

Abstract

Our objective was to validate the International Harmonization Project (IHP) positron emission tomography (PET) response criteria and correlate with the Deauville criteria and diagnostic computed tomography-based (dCT) lesion size changes. All patients were recruited prospectively to the Cancer and Leukemia Group B (CALGB) 50203 trial for the treatment of stage I-II, non-bulky Hodgkin lymphoma (HL). [(18)F]Fluorodeoxyglucose (FDG) PET and dCT were performed at baseline and after two doxorubicin, vinblastine and gemcitabine (AVG) cycles (PET-2, dCT-2) in 88 patients. IHP and Deauville criteria and percent decrease in the sum of the products of the perpendicular diameters (%SPPD) after two cycles were correlated with progression-free survival (PFS). After a median follow-up of 3.3 years, 23.9% of patients relapsed/progressed (3-year PFS 77%). By IHP, the 2-year PFS was 88% and 54% for PET-2 negative and positive groups, respectively (p = 0.0009). Similar results were obtained for Deauville criteria. In a univariate analysis, PET-2 predicted PFS better than %SPPD, and in a combinatorial analysis, in the PET-2 positive group, a negative dCT-2 increased PFS by 27-35%. However, some confidence intervals were large due to small sample sizes. In conclusion, IHP and Deauville criteria-based interpretation of PET-2 was strongly associated with 2-year PFS. The combined analysis of PET-2 with dCT-2 suggested a better predictive value for PFS compared to either test alone. Further studies are under way to confirm these findings.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Progression-Free Survival: Cycle-2 PET alone and PET/CT by IHP criteria(n=88)
Figure 2
Figure 2
Progression-Free Survival: Cycle-2 PET alone and PET/CT by Deauville criteria(n=88)
Figure 3
Figure 3
Progression-Free Survival: %SPPD decrease on dCT-2(n=87)
Figure 4
Figure 4
Progression-Free Survival: Cycle-2 by Combined IHP Criteria and %SPPD decrease on dCT-2(n=87)
See this image and copyright information in PMC

Comment in

References

    1. Armitage JO, Weisenburger DD, Hutchins M, et al. Chemotherapy for diffuse large-cell lymphoma–rapidly responding patients have more durable remissions. J ClinOncol. 1986;4:160–164. - PubMed
    1. Haw R, Sawka CA, Franssen E, Berinstein HL. Significance of a partial or slow response to front-line chemotherapy in the management of intermediate-grade or high-grade non-Hodgkin’s lymphoma: a literature review. J ClinOncol. 1994;12:1074–1084. - PubMed
    1. Meyer RM, Gospodarowicz MK, Connors JM, et al. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin’s lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J ClinOncol. 2005;23:4634–4642. - PubMed
    1. Radford JA, Cowan RA, Flanagan M, et al. The significance of residual mediastinal abnormality on the chest radiograph following treatment for Hodgkin’s disease. J ClinOncol. 1988;6:940–946. - PubMed
    1. Lewis E, Bernardino ME, Salvador PG, Cabanillas FF, Barnes PA, Thomas JL. Post-therapy CTdetected mass in lymphoma patients: is it viable tissue? J Comput Assist Tomogr. 1982;6:792–795. - PubMed

Publication types

Substances